doxazosin has been researched along with Disease Exacerbation in 16 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effects of doxazosin, finasteride and combined therapy in men with lower urinary tract symptoms associated with benign prostatic hyperplasia on sexual function, as assessed by the Brief Male Sexual Function Inventory during 4 years." | 9.19 | Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. ( Burrows, PK; Eggers, PW; Fwu, CW; Kirkali, Z; Kusek, JW; McVary, KT, 2014) |
| "5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia." | 9.10 | The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. ( Andriole, GL; Bautista, OM; Clarke, HS; Crawford, ED; Diokno, A; Dixon, CM; Foley, JP; Foster, HE; Jacobs, SC; Kaplan, SA; Kreder, KJ; Kusek, JW; Lepor, H; Lieber, MM; Lucia, MS; McConnell, JD; McVary, KT; Menon, M; Milam, DF; Miller, GJ; Nyberg, LM; Ramsdell, JW; Roehrborn, CG; Schenkman, NS; Slawin, KM; Smith, JA, 2003) |
| "Both doxazosin and terazosin were significantly more likely than finasteride to improve peak urine flow and nocturia, versus finasteride." | 6.46 | Finasteride for benign prostatic hyperplasia. ( Fink, HA; Macdonald, R; Rutks, I; Tacklind, J; Wilt, TJ, 2010) |
| "Medications targeting androgen receptor activity (eg finasteride) or smooth muscle contractility (eg doxazosin) do not resolve lower urinary tract symptoms indicative of lower urinary tract dysfunction in an important subgroup of men." | 5.30 | Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study. ( Leverson, GE; Macoska, JA; McVary, KT; Ricke, WA; Uchtmann, KS, 2019) |
| "We examined the effects of doxazosin, finasteride and combined therapy in men with lower urinary tract symptoms associated with benign prostatic hyperplasia on sexual function, as assessed by the Brief Male Sexual Function Inventory during 4 years." | 5.19 | Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. ( Burrows, PK; Eggers, PW; Fwu, CW; Kirkali, Z; Kusek, JW; McVary, KT, 2014) |
| "Hypertension treatment with doxazosin or HCTZ resulted in a comparable change in arterial IMT after three years, in spite of differences in effect on plasma lipids." | 5.10 | Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. ( Birkenhägeri, JC; de Groot, E; de Heide, LH; de Ridder, MA; Hoogerbrugge, N; Jansen, H; Stijnen, T, 2002) |
| "5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia." | 5.10 | The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. ( Andriole, GL; Bautista, OM; Clarke, HS; Crawford, ED; Diokno, A; Dixon, CM; Foley, JP; Foster, HE; Jacobs, SC; Kaplan, SA; Kreder, KJ; Kusek, JW; Lepor, H; Lieber, MM; Lucia, MS; McConnell, JD; McVary, KT; Menon, M; Milam, DF; Miller, GJ; Nyberg, LM; Ramsdell, JW; Roehrborn, CG; Schenkman, NS; Slawin, KM; Smith, JA, 2003) |
| "Both doxazosin and terazosin were significantly more likely than finasteride to improve peak urine flow and nocturia, versus finasteride." | 2.46 | Finasteride for benign prostatic hyperplasia. ( Fink, HA; Macdonald, R; Rutks, I; Tacklind, J; Wilt, TJ, 2010) |
| "Secondary goal is inhibition of disease progression." | 2.44 | [Benign prostatic hyperplasia: medical therapy]. ( Gratzke, C; Reich, O; Schlenker, B; Seitz, M; Stief, CG; Weidlich, P, 2007) |
| " Frailty may contribute to both symptom progression and serious adverse events (SAEs), shifting the balance of benefits and harms of drug therapy." | 1.62 | Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. ( Bauer, SR; Covinsky, K; Ensrud, KE; Liu, TT; McVary, KT; Newman, JC; Ricke, WA; Suskind, AM; Walter, LC, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, SR | 1 |
| Walter, LC | 1 |
| Ensrud, KE | 1 |
| Suskind, AM | 1 |
| Newman, JC | 1 |
| Ricke, WA | 2 |
| Liu, TT | 1 |
| McVary, KT | 6 |
| Covinsky, K | 1 |
| Gupta, N | 1 |
| Rogers, T | 1 |
| Holland, B | 1 |
| Helo, S | 1 |
| Dynda, D | 1 |
| Macoska, JA | 1 |
| Uchtmann, KS | 1 |
| Leverson, GE | 1 |
| Lin, VC | 2 |
| Liao, CH | 2 |
| Wang, CC | 1 |
| Kuo, HC | 2 |
| Fwu, CW | 1 |
| Eggers, PW | 1 |
| Kirkali, Z | 1 |
| Burrows, PK | 1 |
| Kusek, JW | 3 |
| Tacklind, J | 1 |
| Fink, HA | 1 |
| Macdonald, R | 1 |
| Rutks, I | 1 |
| Wilt, TJ | 1 |
| Heras, M | 1 |
| Saiz, A | 1 |
| Pardo, J | 1 |
| Fernández-Reyes, MJ | 1 |
| Sánchez, R | 1 |
| Alvarez-Ude, F | 1 |
| Hoogerbrugge, N | 1 |
| de Groot, E | 1 |
| de Heide, LH | 1 |
| de Ridder, MA | 1 |
| Birkenhägeri, JC | 1 |
| Stijnen, T | 1 |
| Jansen, H | 1 |
| Gonzalez, CM | 1 |
| McConnell, JD | 2 |
| Roehrborn, CG | 2 |
| Bautista, OM | 2 |
| Andriole, GL | 1 |
| Dixon, CM | 1 |
| Lepor, H | 1 |
| Nyberg, LM | 2 |
| Clarke, HS | 1 |
| Crawford, ED | 2 |
| Diokno, A | 1 |
| Foley, JP | 1 |
| Foster, HE | 1 |
| Jacobs, SC | 1 |
| Kaplan, SA | 1 |
| Kreder, KJ | 1 |
| Lieber, MM | 1 |
| Lucia, MS | 1 |
| Miller, GJ | 1 |
| Menon, M | 1 |
| Milam, DF | 1 |
| Ramsdell, JW | 1 |
| Schenkman, NS | 1 |
| Slawin, KM | 2 |
| Smith, JA | 2 |
| Hausmann, R | 1 |
| Thalmann, G | 1 |
| Reich, O | 2 |
| Steif, CG | 1 |
| Wilson, SS | 1 |
| Lieber, MC | 1 |
| Meehan, AG | 1 |
| Noble, WR | 1 |
| Schlenker, B | 1 |
| Gratzke, C | 1 |
| Weidlich, P | 1 |
| Seitz, M | 1 |
| Stief, CG | 1 |
| Ukhal', MI | 1 |
| Ukhal', GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Traditional Chinese Medicine VGH-BPH1 on Patients With Benign Prostatic Hyperplasia: A Double-blinded Randomized Placebo-controlled Cross-over Study[NCT03829904] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2019-03-06 | Completed | ||
| Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of Org 3236 Tablets in Men With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia (BPH)[NCT00651807] | Phase 2 | 16 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Business Reasons) | ||
| Medical Therapy of Prostatic Symptoms[NCT00021814] | Phase 3 | 3,407 participants (Actual) | Interventional | 1995-12-31 | Completed | ||
| Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia: A Possible Marker of Progression and Response to Medical Therapy[NCT00407329] | 30 participants (Actual) | Observational | 2006-11-30 | Completed | |||
| Effects of TNF Blockade on Human BPH/LUTS[NCT06062875] | Phase 2 | 70 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy[NCT04288427] | 120 participants (Anticipated) | Interventional | 2020-09-25 | Recruiting | |||
| Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy.[NCT01275521] | Phase 3 | 127 participants (Actual) | Interventional | 2011-01-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for doxazosin and Disease Exacerbation
| Article | Year |
|---|---|
Finasteride for benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug The | 2010 |
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug The | 2003 |
[Benign prostatic hyperplasia: medical therapy].
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Diseas | 2007 |
8 trials available for doxazosin and Disease Exacerbation
| Article | Year |
|---|---|
Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Cystoscopy; Disease Pro | 2018 |
Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Biopsy; Cohort Studies; Disea | 2019 |
Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Azasteroids; Disease Pr | 2014 |
Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Disease Progression; Dose-Res | 2014 |
Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands.
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Carotid Arteries; Disease Progression; Diuretics; D | 2002 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progressio | 2003 |
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Enzyme Inhibitors; Finasteride; Humans | 2006 |
[The effect of symptomatic therapy with the alpha 1-adrenoblocker Cardura in patients with benign prostatic hyperplasia on the course of cardiovascular diseases].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cardiovascular Diseases | 1999 |
5 other studies available for doxazosin and Disease Exacerbation
| Article | Year |
|---|---|
Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
Topics: Aged; Aged, 80 and over; Disease Progression; Doxazosin; Drug Therapy, Combination; Drug-Related Sid | 2021 |
5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Biopsy; Chi-Squ | 2015 |
[Rapidly progressive renal failure as the onset of an IgA nephropathy in an elderly patient].
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Biphenyl Compounds; Disease Progression; Diuretics; Doxaz | 2011 |
[Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
Topics: Adrenergic alpha-Antagonists; Controlled Clinical Trials as Topic; Disease Progression; Double-Blind | 2004 |
Finasteride with doxazosin to reduce BPH progression.
Topics: Disease Progression; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hype | 2005 |